Economic evaluation of blood stem-cells autologous transplantation

Economic evaluation of autologous peripheral blood stem cell (PBSC) transpl antation certainly played a role in the very fast substitution from bone ma rrow to BC autograft. Economic evaluation is still ongoing about the optimi zation of the procedure by assessing the cost-effectiveness ratio of each n ew improvement of the technique. Among these improvements we present the ad ministration of high dose CD34(+) cells, the delayed administration of G-CS F and the outpatient management of post-graft follow-up. It is still very r are in the field of health economics to notice such an early and ongoing ec onomic evaluation of an innovation.